Loading institutional data...
Loading institutional data...
Strong institutional accumulation: ownership increased +48.09% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $4.13 today, the market must believe free cash flow compounds 9.8%/yr for a decade (off $2M normalized FCF).
The market's 9.8% is more optimistic than its 1-yr track record.
2-stage DCF · 0.01B shares · net debt $10M
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $2M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 50%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $12M covers the $7M due within a year 1.7× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-09-30 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2024 (no longer broken out).
Cash of $12M fully covers short-term debt of $6M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Nothing notable to watch.
Where each multiple sits in its own 14-yr range · 4th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 37.5 | 35.3 | 28.6 | 38.3 | 25.9 | 29.6 | 24.8 | 22.9 |
| Gross Profit | 62.5 | 32.0 | 71.4 | 61.7 | 74.1 | 70.4 | 75.2 | 77.1 |
| R&D | 53.1 | 77.3 | 30.7 | 8.5 | 3.4 | 2.8 | 2.1 | 3.1 |
| SG&A | 368.2 | 421.3 | 338.3 | 89.9 | 75.0 | 42.5 | 39.6 | 44.0 |
| Operating Income | -388.1 | -575.3 | -621.1 | -108.7 | -53.5 | -2.6 | 11.8 | 11.2 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.2 |
| Net Income | -628.7 | -682.3 | -762.6 | -209.5 | -61.5 | -126.5 | -101.4 | 26.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on SNWV: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.1M 100.0% | $32.6M 100.0% | $20.4M 100.0% | $16.7M 100.0% | $13.0M 100.0% | $4.1M 100.0% | $1.5M 100.0% | $1.9M 100.0% | $739K 100.0% | $1.4M 100.0% |
| Cost of Revenue | $10.1M 22.9% | $8.1M 24.8% | $6.0M 29.6% | $4.3M 25.9% | $5.0M 38.3% | $1.2M 28.6% | $539K 35.3% | $694K 37.5% | $242K 32.8% | $565K 41.1% |
| Gross Profit | $34.0M 77.1% | $24.6M 75.2% | $14.4M 70.4% | $12.4M 74.1% | $8.0M 61.7% | $2.9M 71.4% | $490K 32.0% | $1.2M 62.5% | $497K 67.2% | — |
| Research & Development | $1.4M 3.1% | $673K 2.1% | $579K 2.8% | $567K 3.4% | $1.1M 8.5% | $1.2M 30.7% | $1.2M 77.3% | $982K 53.1% | $1.3M 175.0% | $1.1M 82.0% |
| Selling, General & Admin | $19.4M 44.0% | $12.9M 39.6% | $8.7M 42.5% | $12.6M 75.0% | $11.7M 89.9% | $13.7M 338.3% | $6.4M 421.3% | $6.8M 368.2% | $3.0M 406.8% | $2.7M 194.3% |
| Total Operating Expenses | $29.0M 65.9% | $20.7M 63.4% | $14.9M 73.1% | $21.4M 127.6% | $22.2M 170.4% | $28.1M 692.5% | $9.3M 607.3% | $8.3M 450.6% | $4.3M 585.1% | $4.1M 299.9% |
| Operating Income | $4.9M 11.2% | $3.8M 11.8% | -$540K -2.6% | -$9.0M -53.5% | -$14.1M -108.7% | -$25.2M -621.1% | -$8.8M -575.3% | -$7.2M -388.1% | -$3.8M -517.8% | -$3.3M -241.0% |
| Interest Expense | — | $12.6M 38.5% | — | $12.8M 76.3% | $6.9M 52.9% | $2.0M 49.9% | $1.8M 120.1% | $4.5M 243.0% | $1.1M 154.3% | $855K 62.1% |
| Other Income (Expense), net | $7.0M 15.8% | -$36.9M -113.1% | -$25.3M -123.9% | -$1.3M -8.0% | -$13.1M -100.6% | -$5.7M -141.4% | -$1.6M -107.0% | -$4.5M -240.6% | -$1.7M -232.0% | -$3.1M -226.9% |
| Pretax Income | $11.9M 27.0% | -$33.1M -101.3% | — | — | — | — | — | — | — | — |
| Income Tax Expense | $86K 0.2% | $27K 0.1% | $4K 0.0% | $2K 0.0% | $28K 0.2% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% |
| Net Income | $11.8M 26.8% | -$33.1M -101.4% | -$25.8M -126.5% | -$10.3M -61.5% | -$27.3M -209.5% | -$30.9M -762.6% | -$10.4M -682.3% | -$11.6M -628.7% | -$5.5M -749.9% | -$6.4M -467.9% |
| Per Share | ||||||||||
| EPS (Basic) | $1.38 | $-7.41 | $-12.19 | $-0.02 | $-0.05 | $-0.08 | $-0.05 | — | — | — |
| EPS (Diluted) | $0.41 | $-7.41 | $-12.19 | $-0.02 | $-0.05 | $-0.08 | $-0.05 | — | — | — |
| Weighted Avg Shares (Basic) | 8.6M | 4.5M | 2.1M | 549.5M | 518.4M | 378.1M | 203.6M | — | — | — |
| Weighted Avg Shares (Diluted) | 9.1M | 4.5M | 2.1M | 549.5M | 518.4M | 378.1M | 203.6M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| SNWV | $35M | 10.1× | 7.7× | 0.8× | 35.0% | 77.1% | 26.8% | 730% | 50.2% | 3.7× | 62 |
Peers = companies sharing SNWV's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.